Question

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

1 comment1

Total Forecasters40

Community Prediction80.8% (77.1% - 85%)

Make a Prediction

50%

community: 80.8%

Learn more about scores here.

Authors:

casens

Opened:

Closes:

Scheduled resolution:

Health & Pandemics

Food and Drug Administration

Americans Are Less Obese Than Before

Newsweek•Dec 18, 2024

Novo Nordisk’s next-generation weight-loss drug CagriSema matches Lilly’s Zepbound in major trial, but doesn’t surpass it

CNN•Dec 20, 2024

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

New York Post•Dec 21, 2024

Learn more about Metaculus NewsMatch

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

59.7%

Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?

0.7%

Comments

? comments

Authors:

casens

Opened:

Closes:

Scheduled resolution:

Health & Pandemics

Food and Drug Administration

Americans Are Less Obese Than Before

Newsweek•Dec 18, 2024

Novo Nordisk’s next-generation weight-loss drug CagriSema matches Lilly’s Zepbound in major trial, but doesn’t surpass it

CNN•Dec 20, 2024

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

New York Post•Dec 21, 2024

Learn more about Metaculus NewsMatch

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

59.7%

Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?

0.7%

Take Our 🏆Quarterly Cup🏆 Survey

MetaculusM

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

Make a Prediction

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?

Comments

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?